p.175 抽出テキスト

Opin 2009; 25: 2877‒85 10) Lennernäs B, Frank‒Lissbrant I, Lennernäs H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med 2010; 24: 286‒93 11) Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo‒controlled, double‒blind, multiple‒crossover study of Fentanyl Pectin Nasal Spray(FPNS)in the treatment of breakthrough cancer pain. Pain 2010; 151: 617‒24 12) Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film(FBSF)for breakthrough pain in patients with cancer: a randomized, double‒blind, placebo‒controlled study. Ann Oncol 2010; 21: 1308‒14 13) Fallon M, Reale C, Davies A, et al.; Fentanyl Nasal Spray Study 044 Investigators Group. Efficacy and safety of fentanyl pectin nasal spray compared with immediate‒release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double‒blind, double‒dummy multiple‒crossover study. J Support Oncol 2011; 9: 224‒31 14) Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double‒blind, placebo‒controlled study. Curr Med Res Opin 2012; 28: 859‒70 15) Kosugi T, Hamada S, Takigawa C, et al. A randomized, double‒blind, placebo‒controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. J Pain Symptom Manage 2014; 47: 990‒1000 16) Novotna S, Valentova K, Fricova J, et al. A randomized, placebo‒controlled study of a new sublingual formulation of fentanyl citrate(fentanyl ethypharm)for breakthrough pain in opioid‒treated patients with cancer. Clin Ther 2014; 36: 357‒67 17) Shimoyama N, Gomyo I, Teramoto O, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol 2015; 45: 189‒96 18) Shimoyama N, Gomyo I, Katakami N, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo‒controlled, double‒blind phase III trial. Int J Clin Oncol 2015; 20: 198‒206 19) Thronæs M, Popper L, Eeg M, et al. Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain. Clin Ther 2015; 37: 585‒96 20) Mercadante S, Adile C, Cuomo A, et al. Fentanyl buccal tablet vs. oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study. J Pain Symptom Manage 2015; 50: 579‒86 21) Mercadante S, Aielli F, Adile C, et al. Fentanyl pectin nasal spray versus oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a comparative study. J Pain Symptom Manage 2016; 52: 27‒34 22) Zecca E, Brunelli C, Centurioni F, et al. Fentanyl sublingual tablets versus subcutaneous morphine for the management of severe cancer pain episodes in patients receiving opioid treatment: a double‒blind, randomized, noninferiority trial. J Clin Oncol 2017; 35: 759‒65 23) Mercadante S, Gatti A, Porzio G, Dosing fentanyl buccal tablet for breakthrough cancer pain:

dose titration versus proportional doses. Curr Med Res Opin 2012; 28: 963‒8